Mark Wholey

Review of PQ Bypass, Inc.

As a Field Director for the company, I am encourag...

As a Field Director for the company, I am encouraged from what clinicians are saying about our technology. "DETOUR ll provides a revolutionary bypass option in CLI patients that is less invasive and allows less procedural time in the OR, CCL, or IR suites". The comments I hear regarding our TORUS ll SFA study is "our graft based on its radial strength could provide better scaffolding in heavily calcified lesion". Physicians always want more choices in providing optimal outcomes.